Gujarat Themis Biosyn announces €158M acquisition of Sanofi's global anti-TB and anti-infective product portfolio.
The asset-light acquisition includes 13 products across 55+ countries with €62M FY2025 revenue and no manufacturing transfer.
Deal funded by debt-equity mix and subject to antitrust/FDI approvals, expected to be EPS accretive with margin expansion potential.
Strategic move provides immediate global market access and forward integration opportunities from fermentation to finished dosage.